ClinicalTrials.gg
CompletedNCT02658448Updated Feb 1, 2021Results posted

GTx-024 as a Treatment for Stress Urinary Incontinence in Women

A Phase 2 interventional study of GTx-024 in Stress Urinary Incontinence, sponsored by GTx. Completed at 3 sites in United States. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by GTx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Urinary Incontinence, Stress with a site in United States — 27 open to participants now, 40 under way, 3 of them phase 3. Urinary Incontinence, Stress · United States.

Enrollment
144th of 163
19 · median 98
Started
2016
with 6 others
Phase 2
12 of 189
1 open now
Registered
76th of 189
by date
Lead sponsor
4 of 189
GTx

Among the 189 studies in Urinary Incontinence, Stress with a site in United States, this one is the 144th largest by enrollment of the 163 interventional ones that give a count, is one of 7 that started in 2016, is one of 12 in phase 2, and was the 76th registered.

Urinary Incontinence, Stress

653 studies on the registry are indexed under Urinary Incontinence, Stress; 122 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

27 of the 189 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Incontinence, Stress studies recruiting now, 42 (56%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether GTx-024 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.

03

Conditions studied

  • Stress Urinary Incontinence
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Give voluntary, written and signed,
  • Female
  • Age18 to 80 years old be clinically confirmed as . Subjects must have undergone the onset of spontaneous, medically induced or surgical menopause prior to the start of this study. Spontaneous menopause is defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy
  • SUI symptoms for at least 6 months duration
  • Predominant SUI (MESA questionnaire)
  • 24 hour pad weight >3 gms at baseline
  • A minimum of 1 SUI episode per day, in the 3 day diary
  • 3-15 SUI episodes per day, averaged over 3 days, in the 3 day diary
  • Serum and ALT within normal limits
  • Total within normal limits
  • Positive Bladder Stress Test during screening
  • Subject agrees to not start any new treatment (medication or otherwise) that is known to affect lower urinary tract function throughout the treatment and follow up periods
  • Subject agrees to maintain on a stable dose of any medication known to affect lower urinary tract function, including but not limited to anticholinergics, tricyclic antidepressants, or alpha-adrenergic blockers, throughout the treatment and follow-up period

Exclusion criteria

Exclusion Criteria:

  • Pelvic floor physical therapy in a clinical setting within 30 days prior to screening
  • History of pelvic radiation treatment
  • History of urethral diverticula
  • History of urethral sling, anterior prolapse repair, ureteral bulking agents and/or other SUI procedure or surgery
  • Known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other significant urological findings, including pelvic floor abnormalities which, in the judgement of the investigator, could impact treatment
  • Urinary incontinence of neurogenic etilogy
  • Patient is morbidly obese (defined as 100 pounds over their ideal body weight, or 40 or greater)
  • Chronic hepatitis
  • Hepatic cirrhosis
  • and/or hepatitis A, B, or C
  • Subjects taking systemic hormone products
  • Subjects with a history of breast or endometrial cancer
  • Myocardial infarction or arterial thromboembolic events within 6 months prior to Baseline, severe or unstable angina, (NYHA) Class III or IV disease, serious uncontrolled cardiac arrhythmia grade II or higher according to NYHA, uncontrolled hypertension (systolic > 150 and/or diastolic > 100 mm Hg)
  • Subjects with an entry measurement of > 5 mm endometrial stripe thickness
  • Clinically confirmed urinary tract infection
  • Any other condition which per investigators' judgment may increase subject risk
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    GTx-024 3 mg

    GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.

    Drug: GTx-024

Interventions

  • GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg

    Also known as: enobosarm

06

What researchers measure

Primary outcomes

  1. The Mean Percent Change in Number of Stress Incontinence Episodes/Day as Assessed by Patient Completion of the 3 Day Voiding Diary

    To describe the effect of 12 weeks of treatment of GTx-024 on the number of stress incontinence episodes/day as assessed by patient completion of the 3 day voiding diary

    Time frame: 12 weeks

Secondary outcomes

  1. Stress Urinary Incontinence as Assessed by 24 Hour Pad Weight Test. Mean Percent Change in Pad Weight

    To describe the effect of 12 weeks of treatment of GTx-024 on SUI as assessed by 24 hour pad weight test. Mean percent reduction in pad weight

    Time frame: 12 weeks

Other outcomes

  1. Number of Participants With Adverse Events

    To describe the safety profile of GTx-024 3 mg PO daily in subjects with stress urinary incontinence.

    Time frame: 12 weeks

07

Results

Posted Feb 1, 2021
Limitations and caveats
Open label, small number of subjects

Participant flow

Participant flow — Overall Study
MilestoneGTx-024 3 mg
Started19
Completed18
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryThe Mean Percent Change in Number of Stress Incontinence Episodes/Day as Assessed by Patient Completion of the 3 Day Voiding Diary

To describe the effect of 12 weeks of treatment of GTx-024 on the number of stress incontinence episodes/day as assessed by patient completion of the 3 day voiding diary

Time frame:
12 weeks
Reported as:
Mean · percent reduction
The Mean Percent Change in Number of Stress Incontinence Episodes/Day as Assessed by Patient Completion of the 3 Day Voiding Diary
percent reductionGTx-024 3 mg
The Mean Percent Change in Number of Stress Incontinence Episodes/Day as Assessed by Patient Completion of the 3 Day Voiding Diary81 (50 to 100)
SecondaryStress Urinary Incontinence as Assessed by 24 Hour Pad Weight Test. Mean Percent Change in Pad Weight

To describe the effect of 12 weeks of treatment of GTx-024 on SUI as assessed by 24 hour pad weight test. Mean percent reduction in pad weight

Time frame:
12 weeks
Reported as:
Mean · percent
Stress Urinary Incontinence as Assessed by 24 Hour Pad Weight Test. Mean Percent Change in Pad Weight
percentGTx-024 3 mg
Stress Urinary Incontinence as Assessed by 24 Hour Pad Weight Test. Mean Percent Change in Pad Weight71 (27 to 126)
Other pre-specifiedNumber of Participants With Adverse Events

To describe the safety profile of GTx-024 3 mg PO daily in subjects with stress urinary incontinence.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsGTx-024 3 mg
Number of Participants With Adverse Events9

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GTx-024 3 mg0/19 (0%)0/19 (0%)9/19 (47.4%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventGTx-024 3 mg
headacheGeneral disorders1/19
nauseaGastrointestinal disorders1/19
muscle sorenessMusculoskeletal and connective tissue disorders1/19
arthritisMusculoskeletal and connective tissue disorders1/19
fatigueGeneral disorders1/19
hot flashEndocrine disorders1/19
insomniaGeneral disorders1/19
urinary frequencyRenal and urinary disorders1/19
acneSkin and subcutaneous tissue disorders1/19
tooth abscessInfections and infestations1/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)GTx-024 3 mg
Mean61.4 (45 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)GTx-024 3 mg
Female19
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GTx-024 3 mg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White16
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)GTx-024 3 mg
United States19
Baseline mean number of stress leaks per day
Baseline mean number of stress leaks per day(number of leaks per day)GTx-024 3 mg
Mean5.17 (3.33 to 10.33)
08

Study locations

3 sites
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • Urologic Consultants of Southeastern Pennsylvania
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Penn Center for Continence and Pelvic Health, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jun 2018, 29 months.

Results were first posted in Feb 2021, 2 years 8 months after primary completion.

Of 15 phase 2 interventional studies under Urinary Incontinence, Stress, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2016
First posted
Jan 18, 2016
StartActual
Jan 2016
Primary completionActual
Jun 2018
CompletionActual
Jun 2018
Results first posted
Feb 1, 2021
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02658448
Lead sponsor
GTx
Responsible party
Sponsor
First posted
Jan 18, 2016
Start date
Jan 2016
Primary completion
Jun 2018
Completion
Jun 2018
Results posted
Feb 1, 2021
Last update
Feb 1, 2021

Study contacts

Kenneth M. Peters, MD
principal investigator · William Beaumont Hospitals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion